Evidence map›Paper›PMID 40016555›Full record

ArticleEuropean radiology2025

Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.

Benedikt M Schaarschmidt, Sebastian Zensen, Claudia Kesch, Thomas Dertnig, Marcel Opitz, Marcel Drews, Jonathan Nadjiri, Michael Forsting, Boris A Hadaschik, Johannes Haubold

Abstract readMulticenter Study
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Benedikt M SchaarschmidtInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. benedikt.schaarschmidt@uk-essen.de.ORCID http://orcid.org/0000-0001-6331-7679
Sebastian ZensenInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Claudia KeschDepartment of Urology, University Hospital Essen, Essen, Germany.
Thomas DertnigInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Marcel OpitzInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Marcel DrewsInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Jonathan NadjiriDepartment of Interventional Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Michael ForstingInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Boris A HadaschikDepartment of Urology, University Hospital Essen, Essen, Germany.
Johannes HauboldInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the success and complications of thermal ablation (TA) based on the voluntary, prospective registry of the German Society for Interventional Radiology and Minimally Invasive Therapy (DeGIR) with 303 participating centers from Germany, Austria, and Switzerland. MATERIALS AND

methodsRegistry data from 2018 until 2023 of 1102 patients with small renal tumors (age: 72.5 ± 11.6 years; female: 33.6%, 370/1102) were analyzed. Hospitals with ≥ 20 TAs were considered high-volume centers. Technical success and complication rates between different parameters were compared using the chi-square or Fisher's exact test, p < 0.05 was considered statistically significant.

resultsPatients were most frequently treated with radiofrequency ablation (RFA, 43.6%, 481/1102), then microwave ablation (MWA, 41.9%, 462/1102) or cryoablation (13.3%, 147/1102). Technical success for heat-based TA (RFA&MWA) was 94.3% (893/947), for cryoablation 97.3% (143/147). RFA&MWA was significantly more successful in lesions ≤ 3 cm (96.1%, 567/590) compared to 3-4 cm lesions (89.8%, 97/108; p = 0.005). In patients treated with cryoablation, no significant differences between sizes could be found (≤ 3 cm: 97.9%, 94/96; 3-4 cm: 85.7%, 12/14; p = 0.078). Complication rate was significantly higher in RFA&MWA of lesions 3-4 cm compared to ≤ 3 cm (≤ 3 cm: 3.9%, 23/590; 3-4 cm: 11.1%, 12/108, p = 0.002), while no significant differences were seen regarding cryoablation (≤ 3 cm: 1.0%, 1/96; 3-4 cm: 0.0%, 0/14; p = 1.000).

conclusionsIn this exploratory analysis of the DeGIR registry, percutaneous TA of small renal masses is technically feasible with low complication rates. Heat-based TAs seem to have lower success rates and higher complication rates in larger tumors. Cryoablation could potentially be a safe alternative for 3- to 4-cm-sized tumors. KEY POINTS: Question How effective is renal thermal ablation (TA) in terms of treatment success and complication rates? Findings In contrast to cryoablation, heat-based thermal ablation has lower success and higher complication rates in tumors measuring 3-4 cm compared to tumors < 3 cm. Clinical relevance Thermal ablation is not influenced by the need for additional techniques such as cooling, protective organ displacement, or temporary vessel occlusion. For small renal tumors, TA is an effective and safe treatment option. Cryoablation could be beneficial in larger tumors.

Indexed as

Catheter AblationKidney NeoplasmsRegistriesAgedAged, 80 and overAustriaCryosurgeryFemaleGermanyHumansMaleMiddle AgedMinimally Invasive Surgical ProceduresProspective StudiesRadiofrequency AblationRadiology, InterventionalCryoablationKidneyMicrowave ablationRadiofrequency ablation

Identifiers

PMID40016555
PMCPMC11868359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.